{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T14:50:09Z","timestamp":1772203809390,"version":"3.50.1"},"reference-count":39,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","license":[{"start":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T00:00:00Z","timestamp":1740096000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"the National Key R&D Program of China","award":["2021YFC2702003"],"award-info":[{"award-number":["2021YFC2702003"]}]}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,21]]},"abstract":"<jats:p>This retrospective observational study aimed to evaluate the effectiveness and hepatoprotective effects of combination therapy with tocilizumab (TCZ) and total glycosides of peony (TGP) in treating systemic juvenile idiopathic arthritis (sJIA). Among the 119 sJIA patients enrolled, 49 received TCZ combined with TGP (study group) and 70 received TCZ not combined with TGP (control group). We compared clinical characteristics, 5 liver function indices (alanine aminotransferase [ALT]\/aspartate aminotransferase [AST]\/alkaline phosphatase\/\u03b3-glutamyltransferase\/total bilirubin), transaminase (ALT\/AST) Kaplan\u2013Meier curves, and inflammatory indices between the groups. The study group showed significantly lower rates of abnormal ALT, AST, alkaline phosphatase, and \u03b3-glutamyltransferase levels (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.05). Among patients with abnormal liver function indices, transaminase abnormalities were the most common (87.50%), particularly after the first TCZ administration (44.64%). Analysis of Kaplan\u2013Meier curves for transaminases for different treatment durations indicated significantly lower abnormal rates (ALT\/AST\u2005&gt;\u20051 and 3\u2005\u00d7\u2005upper limit of normal) in the study group (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.05). The Cox regression model and forest plot identified the group with the highest risk ratio (study group vs control group, hazard ratio\u2005=\u20053.985, 95% confidence interval: 1.997\u20137.952) as an independent risk factor for transaminase abnormalities. A comparison of therapeutic outcomes revealed a more obvious decrease in the number of patients with abnormal inflammation indices in the study group before and after treatment. Moreover, the erythrocyte sedimentation rate value in the study group at the last follow-up significantly lower than that in the control group (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.05). The combination of TCZ and TGP effectively reduced inflammation and lowered the incidence of liver injury, suggesting it may be the preferred combination therapy for sJIA.<\/jats:p>","DOI":"10.1097\/md.0000000000041552","type":"journal-article","created":{"date-parts":[[2025,2,24]],"date-time":"2025-02-24T15:00:09Z","timestamp":1740409209000},"page":"e41552","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":1,"title":["Therapeutic and hepatoprotective effect of tocilizumab combined with total glycosides of peony in systemic juvenile idiopathic arthritis"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0007-8164-9950","authenticated-orcid":false,"given":"Liya","family":"Gao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing","family":"Xie","sequence":"additional","affiliation":[{"name":"School of Pharmacy and Bioengineering, Chongqing University of Technology, Chongqing, China."}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhongyu","family":"Ren","sequence":"additional","affiliation":[{"name":"School of Physical Education, Southwest University, Chongqing, China"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoqiong","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2667-3572","authenticated-orcid":false,"given":"Xuemei","family":"Tang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R1-20250805","first-page":"450","article-title":"Progress in pathogenesis and precise diagnosis and treatment of systemic juvenile idiopathic arthritis.","volume":"38","author":"Luo","year":"2023","journal-title":"Chin J Pract Pediatr"},{"key":"R2-20250805","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/j.berh.2018.02.002","article-title":"Systemic juvenile idiopathic arthritis: new insights into pathogenesis and cytokine directed therapies.","volume":"31","author":"Pardeo","year":"2017","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R3-20250805","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1136\/annrheumdis-2018-213030","article-title":"Treating juvenile idiopathic arthritis to target: recommendations of an international task force.","volume":"77","author":"Ravelli","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"R4-20250805","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1136\/annrheumdis-annrheumdis-2014-206747","article-title":"Long-term safety of etanercept and adalimumab compared to methotrexate in patients with juvenile idiopathic arthritis (JIA).","volume":"75","author":"Klotsche","year":"2016","journal-title":"Ann Rheum Dis"},{"key":"R5-20250805","doi-asserted-by":"crossref","first-page":"2934","DOI":"10.3390\/jcm10132934","article-title":"Juvenile idiopathic arthritis-associated chronic uveitis: recent therapeutic approaches.","volume":"10","author":"Quartier","year":"2021","journal-title":"J Clin Med"},{"key":"R6-20250805","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1002\/art.42037","article-title":"2021 American College of rheumatology guideline for the treatment of juvenile idiopathic arthritis: therapeutic approaches for oligoarthritis, temporomandibular joint arthritis, and systemic juvenile idiopathic arthritis.","volume":"74","author":"Onel","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"R7-20250805","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1002\/art.42036","article-title":"2021 American College of rheumatology guideline for the treatment of juvenile idiopathic arthritis: recommendations for nonpharmacologic therapies, medication monitoring, immunizations, and imaging.","volume":"74","author":"Onel","year":"2022","journal-title":"Arthritis Rheumatol"},{"key":"R8-20250805","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1002\/art.41528","article-title":"Efficacy and safety of tocilizumab for polyarticular-course juvenile idiopathic arthritis in the open-label two-year extension of a phase III Trial.","volume":"73","author":"Brunner","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"R9-20250805","first-page":"37","article-title":"Efficacy and safety of tocilizumab on refractory systemic onset juvenile idiopathic arthritis: observation on 16 cases.","volume":"34","author":"Geng","year":"2019","journal-title":"Chin J Pract Pediatr"},{"key":"R10-20250805","first-page":"426","article-title":"Safety of tocilizumab in children with rheumatic immune disease.","volume":"43","author":"Liu","year":"2024","journal-title":"Chin J New Drugs Clin Remedies"},{"key":"R11-20250805","first-page":"8","article-title":"Efficacy and safety of tocilizumab in the treatment of refractory systemic onset juvenile idiopathic arthritis.","volume":"27","author":"Chen","year":"2021","journal-title":"J Pediatr Pharmacy"},{"key":"R12-20250805","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1038\/s41584-020-0419-z","article-title":"Translating IL-6 biology into effective treatments.","volume":"16","author":"Choy","year":"2020","journal-title":"Nat Rev Rheumatol"},{"key":"R13-20250805","first-page":"50","article-title":"Trends and hotspots in the research on drug-induced liver injury in children: a bibliometric analysis.","volume":"33","author":"Chen","year":"2024","journal-title":"China Pharmaceuticals"},{"key":"R14-20250805","first-page":"1066","article-title":"Expert consensus on biological agents and small molecule targeted drugs for juvenile idiopathic arthritis (2022 version).","volume":"37","year":"2022","journal-title":"Chin J Appl Clin Pediatr"},{"key":"R15-20250805","first-page":"62","article-title":"Pharmacological effects and quality control management of total glycosides of peony.","volume":"15","author":"Liu","year":"2018","journal-title":"China Health Industry"},{"key":"R16-20250805","first-page":"850","article-title":"Study on the mechanism of total glucosides of paeony in the treatment of pulmonary interstitial fibrosis in rheumatoid arthritis based on network pharmacology.","volume":"51","author":"Xing","year":"2024","journal-title":"China Animal Husbandry Veterinary Med"},{"key":"R17-20250805","first-page":"129","article-title":"Research progress of TCM on Juvenile idiopathic arthritis.","volume":"36","author":"Zhang","year":"2023","journal-title":"Western J Tradit Chin Med"},{"key":"R18-20250805","first-page":"83","article-title":"Evaluation of the therapeutic effect and safety of total glucosides of paeonia combined with methotrexate on juvenile idiopathic arthritis.","volume":"10","author":"Hang","year":"2024","journal-title":"World J Complex Med"},{"key":"R19-20250805","first-page":"128","article-title":"Effect of total glucosides of white paeony combined with methotrexate in the treatment of juvenile ldiopathic arthritis.","volume":"21","author":"Zhu","year":"2024","journal-title":"Med Innovation China"},{"key":"R20-20250805","doi-asserted-by":"crossref","first-page":"8292486","DOI":"10.1155\/2016\/8292486","article-title":"Assessment of the therapeutic effect of total glucosides of peony for juvenile idiopathic arthritis: a systematic review and meta-analysis.","volume":"2016","author":"Cai","year":"2016","journal-title":"Evid Based Complement Alternat Med"},{"key":"R21-20250805","first-page":"390","article-title":"International League of Associations for Rheumatology classification of juvenile idiopathic arthritis: second revision, Edmonton, 2001.","volume":"31","author":"Petty","year":"2004","journal-title":"J Rheumatol"},{"key":"R22-20250805","doi-asserted-by":"crossref","first-page":"190","DOI":"10.3899\/jrheum.180168","article-title":"Toward new classification criteria for juvenile idiopathic arthritis: first steps, pediatric rheumatology international trials organization international consensus.","volume":"46","author":"Martini","year":"2019","journal-title":"J Rheumatol"},{"key":"R23-20250805","first-page":"397-","article-title":"Chinese guideline for diagnosis and management of drug-induced liver injury (2023 Version).","volume":"28","author":"Ma","year":"2023","journal-title":"Chin J Gastroenterol"},{"key":"R24-20250805","first-page":"327","article-title":"Chinese expert consensus on diagnosis and treatment of systemic juvenile idiopathic arthritis (2023 edition).","volume":"38","author":"Zhou","year":"2023","journal-title":"Chin J Pract Pediatr"},{"key":"R25-20250805","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1002\/art.40176","article-title":"Transaminase levels and hepatic events during tocilizumab treatment: pooled analysis of long-term clinical trial safety data in rheumatoid arthritis.","volume":"69","author":"Genovese","year":"2017","journal-title":"Arthritis Rheumatol"},{"key":"R26-20250805","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/liv.14766","article-title":"A case series analysis of serious exacerbations of viral hepatitis and non-viral hepatic injuries in tocilizumab-treated patients.","volume":"41","author":"Biehl","year":"2021","journal-title":"Liver Int"},{"key":"R27-20250805","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1080\/14397595.2018.1546357","article-title":"IL-6 inhibitor for the treatment of rheumatoid arthritis: a comprehensive review.","volume":"29","author":"Ogata","year":"2019","journal-title":"Mod Rheumatol"},{"key":"R28-20250805","first-page":"89","article-title":"Identifying drug-induced liver injury associated with inflammation-drug and drug-drug interactions in pharmacologic treatments for COVID-19 by bioinformatics and system biology analyses: the role of pregnane X Receptor.","volume":"13","author":"Huang","year":"8041","journal-title":"Front Pharmacol"},{"key":"R29-20250805","first-page":"369","article-title":"Analysis of the literature on adverse reactions to tocilizumab.","volume":"30","author":"Shu","year":"2021","journal-title":"Chin J New Drugs"},{"key":"R30-20250805","first-page":"533","article-title":"Mining and analysis of tocilizumab adverse reaction signals based upon real world,.","volume":"41","author":"Wng","year":"2021","journal-title":"Chin J Hospital Pharmacy"},{"key":"R31-20250805","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1556\/650.2022.32590","article-title":"[COVID\u201319-associated liver enzyme elevation is probably multifactorial].","volume":"163","author":"G\u00e1sp\u00e1r","year":"2022","journal-title":"Orv Hetil"},{"key":"R32-20250805","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1080\/14740338.2017.1303479","article-title":"Safety of tocilizumab in the treatment of juvenile idiopathic arthritis.","volume":"16","author":"Machado","year":"2017","journal-title":"Expert Opin Drug Saf"},{"key":"R33-20250805","first-page":"16-","article-title":"Research progress of tocilizumab-associated adverse reactions.","volume":"18","author":"Zuo","year":"2020","journal-title":"Clin Medication J"},{"key":"R34-20250805","doi-asserted-by":"crossref","first-page":"4568","DOI":"10.1093\/rheumatology\/keab047","article-title":"Subcutaneous dosing regimens of tocilizumab in children with systemic or polyarticular juvenile idiopathic arthritis.","volume":"60","author":"Ruperto","year":"2021","journal-title":"Rheumatology (Oxford)"},{"key":"R35-20250805","first-page":"433","article-title":"Protective effects of paeoniflorin on acute liver injury induced by lipopolysaccharide in mice.","volume":"32","author":"Liu","year":"2016","journal-title":"Chin J Clin Pharmacol"},{"key":"R36-20250805","first-page":"244","article-title":"Protective effects of total glucosides of paeony and lts main components paeoniflorin and albiflorin in carbon tetrachloride-induced acute liver injury.","volume":"38","author":"Ren","year":"2020","journal-title":"Chin Arch Tradit Chin Med"},{"key":"R37-20250805","first-page":"876","article-title":"Guideline for primary care of drug-induced liver injury: practice version (2019).","volume":"19","year":"2020","journal-title":"Chin J General Practitioners"},{"key":"R38-20250805","first-page":"1885","article-title":"Effect and mechanism of total glucosides of Paeoniae Radix Alba on combined model of chemical liver injury and liver yin deficiency syndrome in rats.","volume":"51","author":"Jia","year":"2020","journal-title":"Chin Tradit Herbal Drugs"},{"key":"R39-20250805","doi-asserted-by":"crossref","first-page":"107452","DOI":"10.1016\/j.pharmthera.2019.107452","article-title":"Anti-inflammatory and immunoregulatory effects of paeoniflorin and total glucosides of paeony.","volume":"207","author":"Zhang","year":"2020","journal-title":"Pharmacol Ther"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041552","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T17:22:33Z","timestamp":1754414553000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041552"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,21]]},"references-count":39,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000041552","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,21]]}}}